Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics

(149)Tb represents a powerful alternative to currently used α-emitters: the relatively short half-life (T(1/2) = 4.1 h), low α-energy (3.97 MeV, I(α) = 16.7 %), absence of α-emitting daughters and stable coordination via DOTA are favorable features for potential clinical application. In this letter,...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Cristina, Vermeulen, Christiaan, Köster, Ulli, Johnston, Karl, Türler, Andreas, Schibli, Roger, van der Meulen, Nicholas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843804/
https://www.ncbi.nlm.nih.gov/pubmed/29564382
http://dx.doi.org/10.1186/s41181-016-0008-2
Descripción
Sumario:(149)Tb represents a powerful alternative to currently used α-emitters: the relatively short half-life (T(1/2) = 4.1 h), low α-energy (3.97 MeV, I(α) = 16.7 %), absence of α-emitting daughters and stable coordination via DOTA are favorable features for potential clinical application. In this letter, we wish to highlight the unique characteristics of (149)Tb for PET imaging, based on its positron emission (E(β+mean) = 730 keV, I(β+) = 7.1 %) in addition to it’s a therapeutic value. To this end, a preclinical study with a tumor-bearing mouse is presented. The perspective of alpha-PET makes (149)Tb highly appealing for radiotheragnostic applications in future clinical trials.

Ejemplares similares